SUNJIN BEAUTY SCIENCE Spins Off Clinical Research Unit to Sharpen Focus, but 2025 Earnings Decline Raises Concerns
Extraordinary general meeting to approve division: SUNJIN BEAUTY SCIENCE will hold an EGM on June 10, 2026 to approve a physical division of its clinical research business.
Division structure: The new entity, Sunjin Clinical Research Center (tentative), will be a wholly-owned subsidiary through a simple physical division; all 100,000 shares (par value 500 won) will be allocated to the parent company, resulting in no dilution for existing shareholders.
Rationale: The spin-off aims to enhance data credibility, eliminate conflicts of interest, and establish specialized management for each business segment, ultimately improving enterprise value.
Financial impact of division: Assets transferred to the new company amount to approximately 2.9 billion won (including 2.17 billion won in tangible assets and 0.46 billion won in cash). The parent's total equity remains unchanged.
2025 financial performance: Revenue fell to 68.8 billion won (-5.2% YoY), operating profit plunged to 3.17 billion won (-65.8%), and net income dropped to 6.48 billion won (-34.5%). EPS was 540 won (vs. 824 won in 2024).
Debt increase: Total borrowings rose from 56.2 billion won in 2024 to 68.2 billion won in 2025, with the debt-to-equity ratio increasing from 91.4% to 99.8%.
Shareholder return: No mention of share buybacks, cancellations, or dividends. Appraisal rights are available for dissenting shareholders.
[AI Comprehensive Analysis]While the physical division may improve business focus and transparency in the long run, it does not provide immediate shareholder returns. The weak 2025 earnings and rising debt are near-term concerns, and the spin-off's benefits will take time to materialize.
KOSDAQ Filing Information
Filing: Notice of Convocation of Shareholders' Meeting